Pro Share Advisors LLC Gritstone Bio, Inc. Transaction History

Pro Share Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.62 - $2.35 $2,555 - $9,684	-4,121 Reduced 25.44%	12,076 $7,000
Q1 2024 May 08, 2024	BUY	$1.96 - $2.9 $3,277 - $4,848	1,672 Added 11.51%	16,197 $41,000
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $3,792 - $8,444	-2,963 Reduced 16.94%	14,525 $29,000
Q3 2023 Nov 13, 2023	BUY	$1.19 - $2.26 $380 - $723	320 Added 1.86%	17,488 $30,000
Q2 2023 Aug 10, 2023	BUY	$1.66 - $3.03 $28,498 - $52,019	17,168 New	17,168 $33,000
Q2 2022 Aug 01, 2022	SELL	$1.77 - $4.34 $26,622 - $65,277	-15,041 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$4.03 - $12.19 $15,600 - $47,187	-3,871 Reduced 20.47%	15,041 $62,000
Q4 2021 Feb 08, 2022	BUY	$8.76 - $13.71 $165,669 - $259,283	18,912 New	18,912 $243,000
Q3 2021 Nov 12, 2021	SELL	$6.41 - $13.54 $67,151 - $141,845	-10,476 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.13 - $10.2 $85,169 - $106,855	10,476 New	10,476 $96,000
Q1 2020 May 15, 2020	SELL	$5.47 - $11.3 $60,831 - $125,667	-11,121 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$7.07 - $11.61 $78,625 - $129,114	11,121 New	11,121 $100,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.